Arcutis Biotherapeutics Overview
Latest P/E ratio for Arcutis Biotherapeutics: 114.54 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow114.54
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for ARQT is 114.54. That is above the Healthcare sector average of 26.36. Investors often review this figure alongside Arcutis Biotherapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ARQT currently prints 114.54 for P/E ratio, while the sector average sits near 26.36. That is roughly 334.6% above the sector mean. Large gaps often invite a closer look at Arcutis Biotherapeutics's growth, margins, and balance sheet.
A P/E ratio of 114.54 for Arcutis Biotherapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (26.36) and with ARQT's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting ARQT's P/E ratio (114.54), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Arcutis Biotherapeutics's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
